Nanobiotix: From Radioenhancer to Platform Company – J&J Fuel, Curadigm Focus, and Cash to 2028
Full-year 2025 highlights: J&J partnership de-risks NBTXR3, CONVERGE lung data shows early promise, and Curadigm nears IND as cash runway extends into early 2028.
NANO.PA · Earnings Call · 2026-04-01
The J&J Handoff and a New Runway
The full-year 2025 results delivered as promised: Nanobiotix has effectively handed the expensive late-stage execution of NBTXR3 (now JNJ-1900) to Johnson & Johnson, eliminating the vast majority of Phase III funding obligations. The company recognized €32.6M in revenue, almost entirely driven by a one-off accounting adjustment from the amended license agreement. “Under the revised terms, we have removed the vast majority of our funding obligations for the Phase III NANORAY-312 study while retaining significant upside through milestone payments that could total hundreds of millions of euros over the next 24 to 36 months.” — Bart Van Rhijn, Chief Financial and Business Officer · 2026-04-01 This, combined with the $71M nondilutive royalty financing from Healthcare Royalty Partners, extends the cash runway into early 2028 — “beyond anticipated value inflection points.” — Bart Van Rhijn, Chief Financial and Business Officer · 2026-04-01 The runway now comfortably covers the two most anticipated catalysts: the Phase III head-and-neck readout (H1 2027) and the Phase II lung data (early 2027).CONVERGE: Early Signals in Lung Cancer
The most striking clinical development this quarter is the early readout from J&J's randomized Phase II CONVERGE trial in unresectable Stage III non-small cell lung cancer. Though the safety lead-in is small, the response rate is eye-catching: “5 out of 7 patients responding” and “100% disease control.” — Laurent Levy, Co-Founder and Chief Executive Officer · 2026-04-01 Laurent Levy was careful to caveat the data, but highlighted that all 7 patients proceeded to durvalumab, comparing favorably to the ~30% who drop out in the PACIFIC regimen. The company is careful to frame NBTXR3's value via local control — a recurring theme in its new platform strategy. As Levy noted, improving local control in a local-regional disease is the core thesis: “If you can improve the local control and have a strong rate of response and CR, then you can deeply change the PFS and overall survival.” — Laurent Levy, Co-Founder and Chief Executive Officer · 2026-04-01 A full randomized readout is expected in early 2027, and management believes a positive result could trigger a Phase III go-decision without waiting for longer-term survival endpoints.Curadigm: The Next Act
While NBTXR3 drives near-term value, the company is clearly repositioning around the Curadigm platform — a second nanoparticle technology that temporarily occupies the liver to improve the biodistribution of IV-administered therapies. The platform has signed over 20 MTAs with pharma and biotech partners. “We are pushing both because we think building our internal pipeline will go through have a first proof of concept of this product into human.” — Laurent Levy, Co-Founder and Chief Executive Officer · 2026-04-01 Curadigm's IND-enabling work is underway, including GMP manufacturing and preclinical studies. The platform also feeds into the company's immune response narrative, as the nanoprimer's mechanistic benefit could amplify checkpoint inhibitors and other modalities. Prior calls had hinted at the pivot — management had described Curadigm as a platform with “multiple products” and update in H2 2024. “The expectation update we want to give in H2 is about how we're going to build the strategy and business model around this new platform.” — Laurent Levy, Co-Founder and Chief Executive Officer · 2024-05-22 That strategy is now crystallizing, with IND timelines and partnership discussions moving from preclinical to early development.What Changed and Why It Matters
The fundamental shift is organizational: Nanobiotix has transitioned from a development-stage biotech carrying the cost of a large Phase III to a leaner platform company leveraging J&J for NBTXR3's clinical and commercial execution while advancing a proprietary platform. R&D expenses fell 43% year-over-year, and the net loss narrowed to €24M. Management expects 4 clinical trial readouts in 2026, with the final data from MD Anderson's lung re-irradiation trial being a key surrogate for CONVERGE.The combination of extended financial visibility and multiple near-term catalysts positions Nanobiotix to re-rate as a platform story rather than a single-asset name....this trial is very important because it's not like the same population that is treated in CONVERGE, but to a certain extent, could be seen as a surrogate of what we could observe in CONVERGE.